GALECTIN THERAPEUTICS INC (GALT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US3632252025
GALECTIN THERAPEUTICS INC financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -20.09 m USD |
| EBIT | -23.63 m USD |
| Net income | -30.84 m USD |
| Diluted EPS – continuing operations | -0.48 USD |
Full history since 2000, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GALECTIN THERAPEUTICS INC
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
More stocks
- Dbv Technologies SA (DBV.PA)
- Zhangjiagang Zhonghuan Hailu High-End Equipment Co. Ltd. (301040.SZ)
- Hyundai Motor Securities Co. Ltd. (001500.KS)
- XiAn Dagang Road Machinery Co (300103.SZ)
- Hota Industrial Mfg. Co Ltd (1536.TW)
- Zhejiang Meilun Elevator Co Ltd (603321.SS)
- TREACE MEDICAL CONCEPTS, INC. (TMCI)
- Hunan Investment Group Co Ltd (000548.SZ)
- Locaweb Serviços de Internet S.A. (LWSA3.SA)
- Guangdong Anjubao Digital Tech (300155.SZ)
- CoastalSouth Bancshares, Inc. (COSO)
- J.Jill, Inc. (JILL)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.